A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Recruiting

Phase 1

Phase 2

A2B694A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Sponsor:

A2 Biotherapeutics Inc.

Code:

NCT06051695

Conditions

Solid Tumor, Adult

Colorectal Cancer

NSCLC

Non Small Cell Lung Cancer

NSCLC, Recurrent

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

A2B694

xT CDx with HLA-LOH Assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-02. This information was provided to ClinicalTrials.gov by A2 Biotherapeutics Inc. on 2025-03-10.